Literature DB >> 23026278

Management of gastroesophageal junction tumors.

Matthew P Fox1, Victor van Berkel.   

Abstract

Tumors of the gastroesophageal junction have historically been treated as either gastric or esophageal cancer depending on institutional preferences. The Siewert classification system was designed to provide a more precise means of characterizing these tumors. In general, surgical treatment of Siewert 1 tumors is via esophagectomy. Siewert 2 and 3 tumors may be treated with either esophagectomy with proximal gastrectomy or extended total gastrectomy provided negative margins are obtained. All but the earliest stage tumors should be considered for neoadjuvant chemoradiotherapy.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23026278     DOI: 10.1016/j.suc.2012.07.011

Source DB:  PubMed          Journal:  Surg Clin North Am        ISSN: 0039-6109            Impact factor:   2.741


  7 in total

Review 1.  Role of stenting in the palliation of gastroesophageal junction cancer: A brief review.

Authors:  Theodoros E Pavlidis; Efstathios T Pavlidis
Journal:  World J Gastrointest Surg       Date:  2014-03-27

2.  The clinicopathologic characteristics and prognostic factors of gastroesophageal junction tumors according to Siewert classification.

Authors:  Bala Başak Öven Ustaalioğlu; Metin Tilki; Ali Sürmelioğlu; Ahmet Bilici; Can Gönen; Recep Ustaalioğlu; Özlem Balvan; Mehmet Aliustaoğlu
Journal:  Turk J Surg       Date:  2017-03-01

3.  Surgical strategies in true adenocarcinoma of the esophagogastric junction (AEG II): thoracoabdominal or abdominal approach?

Authors:  Susanne Blank; Thomas Schmidt; Patrick Heger; Moritz J Strowitzki; Leila Sisic; Ulrike Heger; Henrik Nienhueser; Georg Martin Haag; Thomas Bruckner; André L Mihaljevic; Katja Ott; Markus W Büchler; Alexis Ulrich
Journal:  Gastric Cancer       Date:  2017-07-06       Impact factor: 7.370

4.  Incidence of microscopically positive proximal margins in adenocarcinoma of the gastroesophageal junction.

Authors:  Fei Gao; Jia Chen; Tao Wang; Gang Wang; Zhihong Zhang; Lizong Shen
Journal:  PLoS One       Date:  2014-02-05       Impact factor: 3.240

5.  Outcomes of the Surgical Treatment for Adenocarcinoma of the Cardia - Single Institution Experience.

Authors:  Stojan Potrc; Arpad Ivanecz; Bojan Krebs; Urska Marolt; Bojan Iljevec; Tomaz Jagric
Journal:  Radiol Oncol       Date:  2017-09-14       Impact factor: 2.991

6.  GEAMP, a novel gastroesophageal junction carcinoma cell line derived from a malignant pleural effusion.

Authors:  Wei Zhang; Taylor A Williams; Ankur S Bhagwath; Jared S Hiermann; Craig D Peacock; D Neil Watkins; Peiguo Ding; Jason Y Park; Elizabeth A Montgomery; Arlene A Forastiere; Chunfa Jie; Brandi L Cantarel; Thai H Pham; David H Wang
Journal:  Lab Invest       Date:  2019-07-10       Impact factor: 5.662

7.  Prognostic value of resected lymph nodes numbers for Siewert II gastroesophageal junction cancer.

Authors:  Sanchuan Lai; Tingting Su; Xingkang He; Zhenghua Lin; Shujie Chen
Journal:  Oncotarget       Date:  2017-12-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.